XML 39 R13.htm IDEA: XBRL DOCUMENT v3.20.4
Discontinued Operations and Business Dispositions
12 Months Ended
Dec. 31, 2020
Discontinued Operations and Business Dispositions  
Discontinued Operations and Business Dispositions

Note 4 — Discontinued Operations and Business Dispositions

The net earnings of discontinued operations include income tax benefits of $24 million in 2020 and $39 million in 2018. The 2020 tax benefits primarily relate to the resolution of various tax positions related to Abbott’s developed markets branded generic pharmaceuticals business which was sold to Mylan Inc. (Mylan) in 2015.  The tax positions relate to years prior to the sale to Mylan.  The 2018 tax benefits primarily relate to the resolution of various tax positions related to the operations of AbbVie Inc. (AbbVie) for years prior to the separation.  Abbott completed the separation of AbbVie, which was formed to hold Abbott’s research-based proprietary pharmaceuticals business, in January 2013.  Abbott retained all liabilities for all U.S. federal and foreign income taxes on income prior to the separation.